

# Philippa C May

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6718152/publications.pdf>

Version: 2024-02-01

29  
papers

666  
citations

840776

11  
h-index

642732

23  
g-index

30  
all docs

30  
docs citations

30  
times ranked

1427  
citing authors

#	ARTICLE	IF	CITATIONS
1	Optimized protocol for a quantitative SARS-CoV-2 duplex RT-qPCR assay with internal human sample sufficiency control. <i>Journal of Virological Methods</i> , 2021, 294, 114174.	2.1	16
2	Chromatin-based, in cis and in trans regulatory rewiring underpins distinct oncogenic transcriptomes in multiple myeloma. <i>Nature Communications</i> , 2021, 12, 5450.	12.8	19
3	Complete remission with incomplete count recovery (CRi) prior to allogeneic HCT for acute myeloid leukaemia is associated with a high non-relapse mortality. <i>Leukemia</i> , 2020, 34, 667-670.	7.2	10
4	Three distinct hematological malignancies from a single germ cell tumor: a case report. <i>Journal of Medical Case Reports</i> , 2020, 14, 222.	0.8	3
5	Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on <i>MIR300</i> Antiproliferative and PP2A-Activating Functions. <i>Blood Cancer Discovery</i> , 2020, 1, 48-67.	5.0	30
6	Distinct Chromatin Accessibility Changes, Aberrant Transcription Factor Networks Combined with Novel Oncogenic Enhancers Characterise Myeloma-Initiating Genetic Events. <i>Blood</i> , 2019, 134, 1769-1769.	1.4	0
7	Abstract 1134: The tumor suppressor activity of miR-300 is detrimental for leukemia development but required for leukemia stem cell maintenance. , 2018, , .		0
8	Lineage-Specific Genes Are Prominent DNA Damage Hotspots during Leukemic Transformation of B Cell Precursors. <i>Cell Reports</i> , 2017, 18, 1687-1698.	6.4	15
9	Striking dyserythropoiesis in a myelodysplastic syndrome. <i>American Journal of Hematology</i> , 2017, 92, 218-218.	4.1	1
10	Abnormal villous morphology mimicking a hydatidiform mole associated with paternal trisomy of chromosomes 3,7,8 and unipaternal disomy of chromosome 11. <i>Diagnostic Pathology</i> , 2016, 11, 20.	2.0	16
11	Cutaneous presentation of an aggressive plasmablastic neoplasm indistinguishable between lymphoma and myeloma. <i>Annals of Hematology</i> , 2015, 94, 691-692.	1.8	4
12	Abstract 1261: Comprehensive failure of intracellular protein homeostasis kills myeloma and solid cancer cells following VCP/p97 inhibition. , 2015, , .		0
13	Excellent outcome after repeated changes of tyrosine kinase inhibitor therapy for chronic myeloid leukaemia in complete cytogenetic response due to minor side effects. <i>British Journal of Haematology</i> , 2014, 164, 608-610.	2.5	3
14	Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma. <i>Blood</i> , 2013, 121, 318-328.	1.4	112
15	Observation of auer rods in crushed cells helps in the diagnosis of acute promyelocytic leukemia. <i>American Journal of Hematology</i> , 2013, 88, 236-236.	4.1	1
16	Double minutes with <i>MYC</i> amplification in a patient with chronic myelomonocytic leukaemia transformed into acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2013, 162, 720-720.	2.5	1
17	Combined Inhibition of p97 and the Proteasome Causes Lethal Disruption of the Secretory Apparatus in Multiple Myeloma Cells. <i>PLoS ONE</i> , 2013, 8, e74415.	2.5	45
18	Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies. <i>Blood</i> , 2013, 121, 2739-2742.	1.4	85

#	ARTICLE	IF	CITATIONS
19	PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. <i>Journal of Clinical Investigation</i> , 2013, 123, 4144-4157.	8.2	192
20	Bone marrow trephine biopsy findings in acute promyelocytic leukemia. <i>American Journal of Hematology</i> , 2012, 87, 109-110.	4.1	1
21	Unexpected pancytopenia following treatment of acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2012, 87, 412-412.	4.1	1
22	Peripheral blood and bone marrow findings in B-cell lymphoma, unclassifiable with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. <i>American Journal of Hematology</i> , 2012, 87, 201-202.	4.1	0
23	Clinical Drug Resistance Linked to Inter-Convertible Phenotypic and Functional States of Tumor-Propagating Cells in Multiple Myeloma.. <i>Blood</i> , 2012, 120, 2909-2909.	1.4	6
24	Bone marrow trephine biopsy findings in B acute lymphoblastic leukaemia of early precursor (Pro-B) subtype. <i>American Journal of Hematology</i> , 2011, 86, 195-196.	4.1	0
25	Bone marrow trephine biopsy findings in myeloma with small B-lymphoid cells and <i>CCND1</i> translocation. <i>American Journal of Hematology</i> , 2011, 86, 1038-1038.	4.1	0
26	EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors. <i>Blood</i> , 2010, 116, 6014-6017.	1.4	29
27	Detection of cryptic and variant IGH-MYC rearrangements in high-grade non-Hodgkin's lymphoma by fluorescence in situ hybridization: implications for cytogenetic testing. <i>Cancer Genetics and Cytogenetics</i> , 2010, 198, 71-75.	1.0	31
28	T cell lymphoblastic leukaemia/lymphoma associated with a microenvironment of thymic asteroid B cells in the bone marrow. <i>Histopathology</i> , 2010, 57, 549-554.	2.9	1
29	hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia. <i>Leukemia</i> , 2010, 24, 1243-1245.	7.2	43